LARD (Lopinavir/r or fosamprenavir/r switch to atazanavir/r or darunavir/r)

Investigator-initiated studies like LARD (Lopinavir/r or fosamprenavir/r switch to atazanavir/r or darunavir/r) ask questions that would otherwise not be addressed anywhere else and have the potential to change HIV and HCV treatment everywhere.

Prompted by studies that indicated coronary artery disease might be a significant medical problem in many HIV-infected patients, the 2011 LARD study asked whether changing drug regimens would result in lower levels of triglycerides and components of total cholesterol. Specifically, it addressed whether switching patients from a regimen containing boosted lopinavir or fosamprenavir to a regimen containing either boosted atazanavir or boosted darunavir would result in lower triglyceride levels.

The study showed similar results for both atazanavir and darunavir regimens: A significant drop in triglyceride levels was observed in both regimens; virologic suppression was maintained in both regimens; CD4 counts were stable in both regimens; quality of life and adherence remained high in both regimens; and drug-related adverse event rates were low in both regimens.

Dr. Cal Cohen, CRI Scientific Director, and Dr. Dan Skiest, Principal Investigator, presented the results of the LARD study at the international 2011 CROI (Conference on Retroviruses and Opportunistic Infections).

Click here to view the abstract and here to view the poster from the presentation.